Thus, the CD47:SIRPα axis is referred to as an innate immune checkpoint (23) and is being targeted in a number of clinical trials in various cancer types including AML, breast cancer, CLL, lymphoma and head neck skin cancer (26, 27). This evidence concerns the gene CD47 and lymphoma.